Figure 10.

Tumor growth inhibition of Bs4Ab-VA, anti-VEGF and anti-Ang2, and their combination using a colon cancer (Colo205) mouse xenograft model. When the tumor reached a volume of approximately 200 mm³, mice (n = 6) were administered intraperitoneally twice per week for four weeks with 14 mg/kg of Bs4Ab-VA, 10 mg/kg of anti-VEGF, anti-Ang2, their combination, and a non-binding isotype antibody. Untreated mice were used as control. 10 mg/kg of each of the two parental antibodies were used for the combination study.